Fig. 4 | Signal Transduction and Targeted Therapy

Fig. 4

From: Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study

Fig. 4

Comprehensive analysis of PBMCs. a Transcriptomic profiling of PBMCs distinguished DCB and NDB groups (n = 41). b, c Full spectrum flow cytometry verified the PBMC transcriptome results and found that compared with NDB, the DCB group had higher baseline B cells, cDC2 and monocytes. d Univariate COX regression analysis identified a significant association between myeloid dendritic cells and prognosis. e, f Kaplan–Meier survival curves for PFS and OS of myeloid dendritic cells

Back to article page